Pakistan’s pharmaceutical landscape has entered a new era as BF Biosciences Limited, one of the country’s leading biopharmaceutical manufacturers, has officially launched Zeptide® (Tirzepatide) — a next generation therapy designed to help patients manage Type 2 Diabetes and obesity more effectively.
The company confirmed the development through a formal notice to the Pakistan Stock Exchange, marking a major milestone for Pakistan’s biopharma industry and its growing capacity to produce advanced, globally recognized medicines.
Revolutionizing Diabetes and Obesity Care
Zeptide® is based on Tirzepatide, a synthetic peptide that acts on two critical receptors GLP 1 and GIP responsible for regulating insulin and glucose levels in the body. This dual-action mechanism makes Zeptide a powerful option for improving blood sugar control while also assisting in weight reduction, a unique benefit for patients struggling with both diabetes and obesity.
Unlike traditional medications, Tirzepatide mimics natural hormones that signal the body to release insulin, slow digestion, and reduce appetite. This combination helps patients manage their condition more comprehensively while lowering risks associated with long term diabetes complications.
Locally Manufactured with Global Standards
What sets Zeptide® apart is that it is produced locally at BF Biosciences’ European technology based manufacturing facility in Pakistan. The medicine comes in a ready to use pre filled syringe, ensuring accuracy, safety, and ease of administration — minimizing dosage errors and improving patient compliance.
The company emphasized that the product has been tested for quality, structure, and potency at leading laboratories both in Pakistan and the United States. These tests validate Zeptide’s reliability and align its manufacturing process with international pharmaceutical standards.
A company representative stated that this development reflects BF Biosciences’ ongoing mission to make high-quality biologics accessible to Pakistani patients while reducing dependence on imported treatments.
A Strategic Milestone for Pakistan’s Biopharma Sector
The introduction of Zeptide® is part of BF Biosciences’ broader expansion plan following its successful IPO proceeds utilization strategy. The company is channeling those funds into strengthening its research, production, and innovation capabilities to support Pakistan’s rapidly evolving healthcare sector.
Over the past decade, BF Biosciences has built a strong reputation as the first biopharmaceutical plant in Pakistan, producing essential medicines across multiple therapeutic areas, including oncology, cardiology, nephrology, and infectious diseases. The company is also recognized for launching Sematide® (Semaglutide), Pakistan’s first locally made GLP 1 product, which became one of the most prescribed treatments for diabetes management.
With Zeptide®, BF Biosciences aims to further consolidate its leadership in advanced diabetes therapies, aligning Pakistan with the latest global trends in metabolic health solutions.
Addressing Pakistan’s Growing Health Crisis
According to credible healthcare sources, Pakistan ranks among the top ten countries worldwide for diabetes prevalence. Millions remain undiagnosed, while obesity continues to rise — particularly among women — contributing to higher risks of metabolic diseases.
Public health experts have long warned that the country faces a “silent epidemic,” where poor lifestyle habits and lack of access to modern medication exacerbate the situation. The availability of Tirzepatide under the Zeptide® brand could significantly improve treatment accessibility and outcomes.
By offering this advanced therapy at the local level, BF Biosciences not only lowers dependency on imported medications but also positions Pakistan as a regional player in the development and manufacturing of biologic drugs.
Looking Ahead: Innovation and Impact
Industry observers believe that Zeptide® could redefine diabetes and obesity management in Pakistan over the next few years. The combination of dual hormone targeting, localized production, and affordable access may allow more patients to achieve better control of their condition without the prohibitive costs often associated with imported drugs.
Furthermore, the successful launch of Zeptide® demonstrates Pakistan’s potential to compete in high-tech pharmaceutical production, a critical step toward long term healthcare sustainability and innovation.
BF Biosciences continues to expand its biopharmaceutical capabilities and strengthen its role in addressing chronic diseases that affect millions of Pakistanis. With Zeptide®, the company reinforces its commitment to “healing through innovation” a message that resonates strongly in an era where locally developed, globally aligned healthcare solutions are more vital than ever.
